RISVAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RISVAN (RISVAN).
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
| Metabolism | Primarily metabolized by CYP2D6 to 9-hydroxyrisperidone (active metabolite), with minor contribution from CYP3A4. |
| Excretion | Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other. |
| Half-life | Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C). |
| Protein binding | 97% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6 L/kg (suggests moderate tissue distribution; not extensively sequestered). |
| Bioavailability | Oral: 85% (not significantly affected by food). |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 12-24 hours (dose-dependent); Intravenous: 4-6 hours (single dose). Duration extends with accumulation in chronic use. |
70 mg orally once daily, with or without food.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | eGFR 30-89 mL/min: No adjustment. eGFR <30 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; use caution due to age-related renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RISVAN (RISVAN).
| Breastfeeding | RISVAN is excreted in human milk; M/P ratio 0.8:1. Potential for serious adverse reactions in nursing infants, including sedation, respiratory depression, and withdrawal. Contraindicated during breastfeeding. Discontinue nursing or drug. |
| Teratogenic Risk | RISVAN is contraindicated in pregnancy due to teratogenicity. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester: Risk of fetal growth restriction, preterm birth, and neurodevelopmental impairment. Fetal toxic effects include encephalopathy and intrauterine death. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
| Serious Effects |
Known hypersensitivity to risperidone or any component of the formulation.
| Precautions | Neuroleptic malignant syndrome, tardive dyskinesia, stroke in elderly dementia patients, hyperglycemia/diabetes, weight gain, hyperprolactinemia, orthostatic hypotension, seizures, leukopenia/neutropenia, and body temperature dysregulation. |
Loading safety data…
| Fetal Monitoring | Maternal: CBC, hepatic and renal function tests, serum drug levels, vital signs, ECG. Fetal: Ultrasound for growth and anatomy, fetal heart rate monitoring, biophysical profile. Neonatal: Observation for withdrawal symptoms, respiratory status, blood glucose. |
| Fertility Effects | May impair female fertility by disrupting menstrual cycle and reducing ovarian reserve. In males, may cause oligospermia and reduced sperm motility. Reversible upon discontinuation. |